Developing effective therapeutics for Alzheimer’s disease has proven to be challenging and with the FDA’s recent delay of Aducanumab’s approval process, there are still no approved disease-modifying therapeutics for this devastating neurodegenerative disorder. The results from targeting amyloid as a disease driver — which at best can be viewed as mixed, and at worst as disappointing — highlight the importance of identifying alternative drug targets. In addition, there is great need for developing new tools for early detection and prediction of disease onset. This one-day symposium, presented by Brain and Behavior Discussion Group, will feature the latest research on topics including neurogenesis, neuroprotection, lifestyle factors, and brain-peripheral organ interaction, with an emphasis on showcasing promising avenues for therapeutic development in AD.
December 3, 2021